Zobrazeno 1 - 10 of 27 pro vyhledávání: '"H. R. Superko"'
1
The Role of Diet, Exercise, and Medication in Blood Lipid Management of Cardiac Patients
Autor: H R Superko, B A Franklin
Publikováno v: The Physician and sportsmedicine. 16(11)
In brief: Results of clinical investigations clearly indicate that aggressive management of blood lipids and lipoproteins can significantly benefit cardiovascular health. This finding is particularly important for patients with diagnosed coronary hea
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::976d37b094524430e5d532e433dfb87a
https://pubmed.ncbi.nlm.nih.gov/27415991
Zobrazit plný text záznamu
2
Abstract 630: Lipoprotein Subclasses by Ion Mobility and First Cardiovascular Events: An Analysis of 11,227 Participants From the JUPITER Trial
Autor: Ronald M. Krauss, Paul M. Ridker, Zhihong Chen, Jay Wohlgemuth, H R Superko, Michael P. Caulfield, Robert J. Glynn, Samia Mora
Publikováno v: Arteriosclerosis, Thrombosis, and Vascular Biology. 34
Background: Ion mobility (IM) measures lipoprotein subclasses based on physically separating particles by their size. It is uncertain how IM lipoproteins compare with standard lipids and apolipoproteins in predicting CVD, and whether they relate to r
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0bd5bb2f6a0e322b47597aac85b04649
https://doi.org/10.1161/atvb.34.suppl_1.630
Zobrazit plný text záznamu
3
Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia
Autor: Robert H. Knopp, Santica M. Marcovina, Moti L. Kashyap, P Alagona, Anne C. Goldberg, S Jenkins, Dennis L. Sprecher, H R Superko, Michael H. Davidson, S D Kafonek
Publikováno v: Metabolism. 47:1097-1104
This study compared the efficacy and safety of a once-a-night, time-release niacin formulation, Niaspan (Kos Pharmaceuticals, Miami Lakes, FL), with plain niacin and placebo for the treatment of primary hypercholesterolemia. The study was conducted i
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e5a778156b2639dab56ac9a8b5e068b
https://doi.org/10.1016/s0026-0495(98)90284-0
Zobrazit plný text záznamu
4
Exercise and Lipoprotein Metabolism
Autor: H. R. Superko
Publikováno v: European Journal of Cardiovascular Prevention & Rehabilitation. 2:310-315
Physical activity can have a significant effect on plasma lipoproteins and lipoprotein metabolism. The effect of exercise on lipoprotein subclasses is often more significant than is reflected by routine measures of lipoprotein cholesterol. These effe
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ac782fd1a39053bc2e43c12074443fbf
https://doi.org/10.1177/174182679500200405
Zobrazit plný text záznamu
5
New aspects of risk factors for the development of atherosclerosis, including small low-density lipoprotein, homocyst(e)ine, and lipoprotein(a)
Autor: H R Superko
Publikováno v: Current Opinion in Cardiology. 10:347-354
The risk factors for coronary artery disease have been expanded in recent years to include several clinically significant metabolic disorders. The small, dense low-density lipoprotein trait is one of the most common inherited coronary artery disease
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cecfb640ac3bc055cc51476b41f5e5fa
https://doi.org/10.1097/00001573-199507000-00002
Zobrazit plný text záznamu
6
Providing patients with pharmacogenetic test results affects adherence to statin therapy: results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) trial
Autor: V. Herrera, J Shabbeer, B Schrader, Barnabie C Agatep, E J Stanek, Felix W. Frueh, James J. Devlin, Scott L. Charland, M Ryvkin, H R Superko
Publikováno v: The pharmacogenomics journal. 14(3)
Despite the clinical benefit of statin therapy and the numerous strategies used to improve adherence, no strategy has used direct communication of genetic test results to the patient as an adherence and persistence motivator. We investigated in a rea
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e09d6e76158c54f5cc28ae5b5dea6351
https://pubmed.ncbi.nlm.nih.gov/23979174
Zobrazit plný text záznamu
7
Coronary artery disease regression. Convincing evidence for the benefit of aggressive lipoprotein management
Autor: H R Superko, Ronald M. Krauss
Publikováno v: Circulation. 90:1056-1069
BACKGROUND Numerous reports suggest that coronary artery disease can regress with lipoprotein manipulation. Many of these reports lack control groups and contain relatively small numbers. METHODS AND RESULTS Ten randomized controlled clinical trials
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa6c4807c738e0be51108c4ed22994e3
https://doi.org/10.1161/01.cir.90.2.1056
Zobrazit plný text záznamu
8
Prediction of native coronary artery disease progression following PTCA or CABG in the Emory Angioplasty Versus Surgery Trial
Autor: Xue-Qiao, Zhao, Andrzej S, Kosinski, Huiman X, Barnhart, H R, Superko, Spencer B, King
Publikováno v: Medical science monitor : international medical journal of experimental and clinical research. 9(2)
The natural history of atherosclerosis progression following revascularization procedures (PTCA or CABG) limits the long-term benefits of these procedures and requires continuation of risk management.Of 392 patients with multivessel disease randomize
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7b767d64d31592ab6304f83b91aa69bc
https://pubmed.ncbi.nlm.nih.gov/12601286
Zobrazit plný text záznamu
10
Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia
Autor: J R, Guyton, A C, Goldberg, R A, Kreisberg, D L, Sprecher, H R, Superko, C M, O'Connor
Publikováno v: The American journal of cardiology. 82(6)
We performed a multicenter, open-label study to determine the long-term safety and efficacy of a new extended-release once-a-night niacin preparation, Niaspan, in the treatment of hypercholesterolemia. Niaspan, 0.5 to 3.0 g once a night at bedtime, w
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d0b8f4512e340083d7787135d4147d39
https://pubmed.ncbi.nlm.nih.gov/9761083
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje